These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16541143)

  • 1. Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials).
    Kelaidi C; Ades L; Chevret S; Sanz M; Guerci A; Thomas X; de Botton S; Raffoux E; Rayon C; Fegueux N; Bordessoule D; Rigal-Huguet F; Link H; Stoppa A; Vekhoff A; Meyer-Monard S; Castaigne S; Dombret H; Degos L; Fenaux P
    Leukemia; 2006 May; 20(5):905-7. PubMed ID: 16541143
    [No Abstract]   [Full Text] [Related]  

  • 2. Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
    Iland HJ; Wei A; Seymour JF
    Best Pract Res Clin Haematol; 2014 Mar; 27(1):39-52. PubMed ID: 24907016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group.
    Bally C; Fadlallah J; Leverger G; Bertrand Y; Robert A; Baruchel A; Guerci A; Recher C; Raffoux E; Thomas X; Leblanc T; Idres N; Cassinat B; Vey N; Chomienne C; Dombret H; Sanz M; Fenaux P; Adès L
    J Clin Oncol; 2012 May; 30(14):1641-6. PubMed ID: 22473162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to manage acute promyelocytic leukemia.
    Mi JQ; Li JM; Shen ZX; Chen SJ; Chen Z
    Leukemia; 2012 Aug; 26(8):1743-51. PubMed ID: 22422168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the role of arsenic in newly diagnosed APL?
    Tallman MS
    Best Pract Res Clin Haematol; 2008 Dec; 21(4):659-66. PubMed ID: 19041605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
    Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
    Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy.
    Montesinos P; González JD; González J; Rayón C; de Lisa E; Amigo ML; Ossenkoppele GJ; Peñarrubia MJ; Pérez-Encinas M; Bergua J; Debén G; Sayas MJ; de la Serna J; Ribera JM; Bueno J; Milone G; Rivas C; Brunet S; Löwenberg B; Sanz M
    J Clin Oncol; 2010 Aug; 28(24):3872-9. PubMed ID: 20625122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing acute promyelocytic leukemia without conventional chemotherapy: is it possible?
    Park JH; Tallman MS
    Expert Rev Hematol; 2011 Aug; 4(4):427-36. PubMed ID: 21801134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
    Quezada G; Kopp L; Estey E; Wells RJ
    Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.
    Esteve J; Escoda L; Martín G; Rubio V; Díaz-Mediavilla J; González M; Rivas C; Alvarez C; González San Miguel JD; Brunet S; Tomás JF; Tormo M; Sayas MJ; Sánchez Godoy P; Colomer D; Bolufer P; Sanz MA;
    Leukemia; 2007 Mar; 21(3):446-52. PubMed ID: 17205057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group.
    Ortega JJ; Madero L; Martín G; Verdeguer A; García P; Parody R; Fuster J; Molines A; Novo A; Debén G; Rodríguez A; Conde E; de la Serna J; Allegue MJ; Capote FJ; González JD; Bolufer P; González M; Sanz MA;
    J Clin Oncol; 2005 Oct; 23(30):7632-40. PubMed ID: 16234524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy.
    Park JH; Tallman MS
    Oncology (Williston Park); 2011 Jul; 25(8):733-41. PubMed ID: 21874835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Don't just stand there, do something: strategies for the prevention of early death in acute promyelocytic leukemia: a commentary.
    Tallman MS; Manji GA
    Blood Cells Mol Dis; 2011 Feb; 46(2):173-4. PubMed ID: 21227722
    [No Abstract]   [Full Text] [Related]  

  • 15. Conventional induction and post-remission therapy in APL: have we arrived?
    Sanz MA; Iacoboni G; Montesinos P
    Best Pract Res Clin Haematol; 2014 Mar; 27(1):33-8. PubMed ID: 24907015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective study of a therapeutic regimen with all-trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia: the Japanese childhood acute myeloid leukaemia cooperative study.
    Imaizumi M; Tawa A; Hanada R; Tsuchida M; Tabuchi K; Kigasawa H; Kobayashi R; Morimoto A; Nakayama H; Hamamoto K; Kudo K; Yabe H; Horibe K; Tsuchiya S; Tsukimoto I
    Br J Haematol; 2011 Jan; 152(1):89-98. PubMed ID: 20735397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks.
    Huang H; Qin Y; Xu R; You X; Teng R; Yang L; Xu M; Liu H
    Leuk Res; 2012 Jul; 36(7):841-5. PubMed ID: 22534100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of additional chromosome abnormalities on the outcome of newly diagnosed acute promyelocytic leukemia treated with red arsenic sulfide and all trans-retinoic acid plus anthracyclin based protocol].
    Lu J; Jiang H; Jiang Q; Bao L; Lu XJ; Zhang Y; Lin W; Liu YR; Huang XJ; Jiang B
    Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(32):2254-7. PubMed ID: 19087672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience.
    Kelaidi C; Chevret S; De Botton S; Raffoux E; Guerci A; Thomas X; Pigneux A; Lamy T; Rigal-Huguet F; Meyer-Monard S; Chevallier P; Maloisel F; Deconinck E; Ferrant A; Fegueux N; Ifrah N; Sanz M; Dombret H; Fenaux P; Adès L
    J Clin Oncol; 2009 Jun; 27(16):2668-76. PubMed ID: 19414681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current management and new approaches in the treatment of APL.
    Tallman MS
    Clin Adv Hematol Oncol; 2003 Oct; 1(10):580-1. PubMed ID: 16258453
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.